Blood News and Research

RSS

Subtype of CD4-positive immune cells in the gut may influence HIV infection outcome

The findings of a new study in monkeys may help clarify why some people infected with HIV are better able to control the virus. They also may pinpoint a target for treatment during early HIV infection aimed at increasing the supply of certain immune cells in the gut, which the study shows could be an important factor in limiting HIV growth in cells throughout the body.

11 Jun 2012

New easy-to-use Bayer blood glucose monitoring system

A new blood glucose monitoring (BGM) system from Bayer, the CONTOUR Next EZ meter and CONTOUR Next test strips, proved easy to use and highly accurate in the hands of intended users -- patients and their healthcare professionals (HCPs) - according to a clinical study presented at the American Diabetes Association 72nd Scientific Sessions in Philadelphia, PA.

11 Jun 2012

Theramine may reduce chronic low back pain

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the company's proprietary medical food Theramine.

11 Jun 2012

Menopausal women with high oestradiol levels at greater risk of strokes

Women are less prone to cardiovascular disease then men; but this difference between the sexes becomes less marked after the menopause. This observation is behind a great deal of received wisdom, where oestrogen is assumed to have a beneficial effect on the heart and blood vessels.

11 Jun 2012

Scientists image structure of bacterium protein coat

Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.

11 Jun 2012

Restoration of normal glucose regulation may prevent diabetes

People with pre-diabetes are significantly less likely to develop diabetes if their blood glucose levels are normalized in time, according to new research by the Colorado School of Public Health and the University of Colorado School of Medicine.

11 Jun 2012

Epo has performance-enhancing effect on brain, may help treat depression, schizophrenia

Sportsmen and women dope with the blood hormone Epo to enhance their performance. Researchers from the University of Zurich now discovered by animal testing that Epo has a performance-enhancing effect in the brain shortly after injection and not only after days by improving oxygen transport in blood. As Epo also increases motivation, it could be useful in treating depression.

11 Jun 2012

Popular low carbohydrate diet leads to increase in cholesterol levels

A 25 year study in Northern Sweden, published in BioMed Central's open access journal Nutrition Journal, is the first to show that a regional and national dietary intervention to reduce fat intake, decreased cholesterol levels, but a switch to the popular low carbohydrate diet was paralleled by in an increase in cholesterol levels.

11 Jun 2012

Rapid test to identify patients not responding to painkiller tramadol

French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.

11 Jun 2012

Powerful new tools can study glycans’ function

Scientists at The Scripps Research Institute have developed chemical compounds that can make key modifications to common sugar molecules ("glycans"), which are found on the surface of all cells in our body. The new study presents powerful new tools for studying these molecules' function, for example in cell signaling and immunity, and for investigating new treatments for chronic inflammation, autoimmune diseases, cancer metastasis, and related conditions.

11 Jun 2012

Data from first feasibility study of artificial pancreas system

Results from the first feasibility study of an advanced first-generation artificial pancreas system were presented today at the 72nd Annual American Diabetes Association Meeting in Philadelphia. Findings from the study indicated that the Hypoglycemia-Hyperglycemia Minimizer (HHM) System was able to automatically predict a rise and fall in blood glucose and correspondingly increase and/or decrease insulin delivery safely.

11 Jun 2012

Nanocontainers can fight against atherosclerosis

In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.

11 Jun 2012

Simple blood test can quickly identify 'poor metabolisers'

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Researchers identify six genes that predispose to migraine without aura

Researchers studied genetic data of more than 11 000 people and found altogether six genes that predispose to migraine without aura. Four of these genes are new and two of them confirm previous findings.

11 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Pre-operative aspirin therapy may reduce risk of acute kidney failure after CABG surgery

Aspirin taken for five days before a heart operation can halve the numbers of patients developing post-operative acute kidney failure, according to research presented at the European Anaesthesiology Congress in Paris.

11 Jun 2012

Poor long-term physical and mental health for many adolescent and young adult cancer survivors

A new analysis has found that many adolescent and young adult cancer survivors have unhealthy behaviors, chronic medical conditions, a poor quality of life, and significant barriers to health care access. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to provide quality follow-up care to adolescent and young adult cancer survivors and to encourage them to live more healthily.

11 Jun 2012

Glucose-lowering regulations in people with prediabetes achieves reduction in progression to diabetes in the long term

People with “prediabetes” (a high risk state for overt type 2 diabetes) who experience a period of normal glucose regulation are 56% less likely to develop diabetes 5∙7 years later, according to a new research Article presented at the American Diabetes Association 72nd Scientific Sessions on Saturday 9 June, and published Online First in The Lancet. This is one of four Articles (all presented at the American Diabetes Association 72nd Scientific Sessions) and a Series of three papers that are part of a special Lancet theme issue on diabetes [1].

11 Jun 2012

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

11 Jun 2012